Physician profile
Michael Chung
NPI 1346878170
$1,318.06
in general payments reported to CMS, 2019-2025
15 companies · $715 in 2025
The $715 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $603 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.84 | 2024-2025 | |
| Lilly USA, LLC | $229.39 | 2024-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $154.49 | 2024-2025 | Libtayo, Dupixent |
| Amgen INC. | $137.67 | 2024 | Otezla |
| Mimedx Group, INC. | $136.82 | 2024 | |
| Janssen Biotech, INC. | $112.53 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $64.12 | 2024-2025 | |
| Galderma Laboratories, L.P. | $39.24 | 2025 | Nemluvio |
| Convatec INC. | $30.39 | 2024 | |
| Organogenesis INC. | $23.50 | 2025 | Via Matrix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.26 | 2025 | Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $19.20 | 2025 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $18.03 | 2025 | Nuzyra |
| Botanix Sb INC | $16.99 | 2025 | Sofdra |
| Kerecis Limited | $14.59 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.